恩瑞格推荐使用量是多少呢？

What is the recommended dosage?

The recommended dose of Enrig is 20mg/kg. 

For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (ie, more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. 

For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. 

In patients who have already responded well to deferoxamine therapy, an initial dose of Enriga equivalent to half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days a week or equivalent, may start with 20 mg/kg if switched to Enrig.)

How to take Enrig:

Enriga should be taken once a day on an empty stomach, at least 30 minutes before a meal, preferably at the same time each day. Tablets should not be chewed or swallowed whole.  

Enriga should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. 

Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before being taken. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Dosage adjustment of Enrego:

Myelosuppression: Interrupt treatment; may restart once cause of cytopenia is determined; contraindicated if platelet count <50,000/mm3;

Cutaneous Toxicity: Rash (Severe): Interrupt treatment; may be reintroduced at lower doses (with future dose escalations) and oral corticosteroids for a short period of time. Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate.

Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding.

Hearing loss or visual impairment: Consider dose reduction or treatment interruption.